Edoxaban versus enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial

详细信息    查看全文

• 作者：Prof Andreas Goette ; MD^a ; ^b ; ^&dagger ; ; ^{andreas.goette@vincenz.de" class="auth_mail" title="E-mail the corresponding author} ; Prof Jose L Merino ; MD^c ; Prof Michael D Ezekowitz ; MBChB^d ; Dmitry Zamoryakhin ; MD^e ; Michael Melino ; PhD^f ; James Jin ; PhD^g ; Michele F Mercuri ; MD^f ; Michael A Grosso ; MD^f ; Victor Fernandez ; BS^f ; Naab Al-Saady ; MD^h ; Natalya Pelekh ; MDⁱ ; Prof Bela Merkely ; MD^j ; Sergey Zenin ; MD^k ; Mykola Kushnir ; MD^l ; Prof Jindrich Spinar ; MD^m ; Prof Valeriy Batushkin ; MDⁿ ; Joris R de Groot ; MD^o ; Prof Gregory Y H Lip ; MD^p ; ^q ; ^&dagger ; ; on behalf of the ENSURE-AF investigators^&Dagger ;
• 刊名：The Lancet
• 出版年：2016
• 出版时间：22-28 October 2016
• 年：2016
• 卷：388
• 期：10055
• 页码：1995-2003
• 全文大小：173 K

文摘

Edoxaban, an oral factor Xa inhibitor, is non-inferior for prevention of stroke and systemic embolism in patients with atrial fibrillation and is associated with less bleeding than well controlled warfarin therapy. Few safety data about edoxaban in patients undergoing electrical cardioversion are available.

Methods

We did a multicentre, prospective, randomised, open-label, blinded-endpoint evaluation trial in 19 countries with 239 sites comparing edoxaban 60 mg per day with enoxaparin–warfarin in patients undergoing electrical cardioversion of non-valvular atrial fibrillation. The dose of edoxaban was reduced to 30 mg per day if one or more factors (creatinine clearance 15–50 mL/min, low bodyweight [≤60 kg], or concomitant use of P-glycoprotein inhibitors) were present. Block randomisation (block size four)—stratified by cardioversion approach (transoesophageal echocardiography [TEE] or not), anticoagulant experience, selected edoxaban dose, and region—was done through a voice-web system. The primary efficacy endpoint was a composite of stroke, systemic embolic event, myocardial infarction, and cardiovascular mortality, analysed by intention to treat. The primary safety endpoint was major and clinically relevant non-major (CRNM) bleeding in patients who received at least one dose of study drug. Follow-up was 28 days on study drug after cardioversion plus 30 days to assess safety. This trial is registered with ClinicalTrials.gov, number NCT02072434.

Findings

Between March 25, 2014, and Oct 28, 2015, 2199 patients were enrolled and randomly assigned to receive edoxaban (n=1095) or enoxaparin–warfarin (n=1104). The mean age was 64 years (SD 10·54) and mean CHA₂DS₂-VASc score was 2·6 (SD 1·4). Mean time in therapeutic range on warfarin was 70·8% (SD 27·4). The primary efficacy endpoint occurred in five (<1%) patients in the edoxaban group versus 11 (1%) in the enoxaparin–warfarin group (odds ratio [OR] 0·46, 95% CI 0·12–1·43). The primary safety endpoint occurred in 16 (1%) of 1067 patients given edoxaban versus 11 (1%) of 1082 patients given enoxaparin–warfarin (OR 1·48, 95% CI 0·64–3·55). The results were independent of the TEE-guided strategy and anticoagulation status.

Interpretation

ENSURE-AF is the largest prospective randomised clinical trial of anticoagulation for cardioversion of patients with non-valvular atrial fibrillation. Rates of major and CRNM bleeding and thromboembolism were low in the two treatment groups.

Funding

Daiichi Sankyo provided financial support for the study.